Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.74 USD
-0.04 (-0.69%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $5.68 -0.06 (-1.05%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Travere Therapeutics (TVTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.67 | $21.00 | $9.00 | 150.77% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Travere Therapeutics comes to $14.67. The forecasts range from a low of $9.00 to a high of $21.00. The average price target represents an increase of 150.77% from the last closing price of $5.85.
Analyst Price Targets (15)
Broker Rating
Travere Therapeutics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 12 are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
3/27/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
3/13/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
1/18/2024 | Piper Sandler | Allison M Bratzel | Hold | Hold |
11/7/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
9/21/2023 | William Blair | Timothy F Lugo | Strong Buy | Hold |
9/19/2023 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
7/18/2023 | Canaccord Genuity | Edward H Nash | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 16 |
Average Target Price | $14.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -0.95 |